tradingkey.logo

ICON PLC

ICLR
查看詳細走勢圖
181.380USD
-6.840-3.63%
收盤 01/09, 16:00美東報價延遲15分鐘
13.85B總市值
24.30本益比TTM

ICON PLC

181.380
-6.840-3.63%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-3.63%

5天

-3.86%

1月

-2.41%

6月

+19.27%

今年開始到現在

-0.46%

1年

-16.88%

查看詳細走勢圖

TradingKey ICON PLC股票評分

單位: USD 更新時間: 2026-01-09

操作建議

ICON PLC當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名32/396位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為205.56。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ICON PLC評分

相關信息

行業排名
32 / 396
全市場排名
128 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
極度看空

ICON PLC亮點

亮點風險
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
行業龍頭
公司營業收入處於行業前列,最新年度總收入8.28B美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入8.28B美元
估值合理
公司最新PE估值24.30,處於3年歷史合理位
機構減倉
最新機構持股81.18M股,環比減少14.08%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉571.00股
活躍度降低
近期活躍度降低,過去20天平均換手率0.06

分析師目標

基於 18 分析師
買入
評級
205.563
目標均價
+4.04%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ICON PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ICON PLC簡介

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
公司代碼ICLR
公司ICON PLC
CEOBalfe (Barry Edward)
網址https://www.iconplc.com/

常見問題

ICON PLC(ICLR)的當前股價是多少?

ICON PLC(ICLR)的當前股價是 181.380。

ICON PLC 的股票代碼是什麼?

ICON PLC的股票代碼是ICLR。

ICON PLC股票的52週最高點是多少?

ICON PLC股票的52週最高點是220.930。

ICON PLC股票的52週最低點是多少?

ICON PLC股票的52週最低點是125.100。

ICON PLC的市值是多少?

ICON PLC的市值是13.85B。

ICON PLC的淨利潤是多少?

ICON PLC的淨利潤為791.47M。

現在ICON PLC(ICLR)的股票是買入、持有還是賣出?

根據分析師評級,ICON PLC(ICLR)的總體評級為買入,目標價格為205.563。

ICON PLC(ICLR)股票的每股收益(EPS TTM)是多少

ICON PLC(ICLR)股票的每股收益(EPS TTM)是7.464。
KeyAI